MRKR vs. EYEN, VYNE, ACXP, BCTX, PMN, APLM, NXTC, XLO, IPA, and UNCY
Should you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include Eyenovia (EYEN), VYNE Therapeutics (VYNE), Acurx Pharmaceuticals (ACXP), BriaCell Therapeutics (BCTX), ProMIS Neurosciences (PMN), Apollomics (APLM), NextCure (NXTC), Xilio Therapeutics (XLO), ImmunoPrecise Antibodies (IPA), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical preparations" industry.
Eyenovia (NASDAQ:EYEN) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership, community ranking and profitability.
Eyenovia has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500.
25.8% of Eyenovia shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 7.8% of Eyenovia shares are held by insiders. Comparatively, 24.1% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Eyenovia had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Eyenovia and 2 mentions for Marker Therapeutics. Eyenovia's average media sentiment score of 0.60 beat Marker Therapeutics' score of 0.22 indicating that Marker Therapeutics is being referred to more favorably in the news media.
Eyenovia received 98 more outperform votes than Marker Therapeutics when rated by MarketBeat users. Likewise, 65.00% of users gave Eyenovia an outperform vote while only 63.39% of users gave Marker Therapeutics an outperform vote.
Eyenovia has a net margin of 0.00% compared to Eyenovia's net margin of -142.62%. Eyenovia's return on equity of -39.89% beat Marker Therapeutics' return on equity.
Eyenovia currently has a consensus target price of $10.00, indicating a potential upside of 1,196.51%. Marker Therapeutics has a consensus target price of $11.00, indicating a potential upside of 166.34%. Given Marker Therapeutics' higher probable upside, equities research analysts clearly believe Eyenovia is more favorable than Marker Therapeutics.
Marker Therapeutics has higher revenue and earnings than Eyenovia.
Summary
Eyenovia beats Marker Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Marker Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Marker Therapeutics Competitors List
Related Companies and Tools
